Evaluation of 2,3-dihydroimidazo[2,1-b]oxazole and imidazo[2,1-b]oxazole derivatives as chemotherapeutic agents

被引:1
作者
Shahin, Afnan, I [1 ]
Zaraei, Seyed-Omar [1 ]
Alzuraiqi, Shahed [2 ]
Abdulateef, Zahaa [2 ]
Abbas, Noora E. [2 ]
Al-Tel, Taleb H. [1 ,2 ]
El-Gamal, Mohammed, I [1 ,2 ,3 ]
机构
[1] Univ Sharjah, Res Inst Med & Hlth Sci, Sharjah 27272, U Arab Emirates
[2] Univ Sharjah, Coll Pharm, Dept Med Chem, Sharjah 27272, U Arab Emirates
[3] Mansoura Univ, Fac Pharm, Dept Med Chem, Mansoura 35516, Egypt
关键词
2,3-dihydroimidazo[2,1-b]oxazole; anticancer; antimicrobial; delamanid; imidazo[2,1-b]oxazole; tuberculosis; ANTITUBERCULOSIS DRUG; DELAMANID; TOXICITY; INHIBIT; AGONIST;
D O I
10.4155/fmc-2023-0147
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Imidazo[2,1-b]oxazole and 2,3-dihydroimidazo[2,1-b]oxazole ring systems are commonly employed in therapeutically active molecules. In this article, the authors review the utilization of these core scaffolds as chemotherapeutic agents from 2018 to 2022. These scaffolds possess many important biological activities including antimicrobial and anticancer, among others. This review covers their biological activities and structure-activity relationships. One of the most important drugs in this class of compounds is the antitubercular agent delamanid. In this paper, the compounds structure-activity relationship and preclinical and clinical trial data are thoroughly presented. [GRAPHICS] .
引用
收藏
页码:1885 / 1901
页数:17
相关论文
共 59 条
[1]   Design, synthesis, and anticancer activity of imidazo[2,1-b]oxazole-based RAF kinase inhibitors [J].
Abdel-Maksoud, Mohammed S. ;
Ammar, Usama M. ;
El-Gamal, Mohammed I. ;
El-Din, Mahmoud M. Gamal ;
Mersal, Karim I. ;
Ali, Eslam M. H. ;
Yoo, Kyung Ho ;
Lee, Kyung-Tae ;
Oh, Chang-Hyun .
BIOORGANIC CHEMISTRY, 2019, 93
[2]   Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold [J].
Abdel-Maksouda, Mohammed S. ;
Ammar, Usama M. ;
Oh, Chang-Hyun .
BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (10) :2041-2051
[3]   Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges [J].
Aghila Rani, Koippallil Gopalakrishnan ;
Hamad, Mohamad A. ;
Zaher, Dana M. ;
Sieburth, Scott McN ;
Madani, Navid ;
Al-Tel, Taleb H. .
EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (04) :365-371
[4]   Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18 [J].
Auchynka, Vera ;
Kumar, Ajay M., V ;
Hurevich, Hennadz ;
Sereda, Yuliia ;
Solodovnikova, Varvara ;
Katovich, Dzmitry ;
Setkina, Svetlana ;
Yedilbayev, Askar ;
Skrahin, Aliaksandr ;
Skrahina, Alena .
MONALDI ARCHIVES FOR CHEST DISEASE, 2021, 91 (01)
[5]   Novel Imidazo[2,1-b]oxazole Derivatives Inhibit Epithelial Cell Transformation and Triple Negative Breast Cancer Tumorigenesis [J].
Bhattarai, Poshan Yugal ;
Oh, Chang-Hyun ;
Kim, Garam ;
Kim, Min Soo ;
Lee, Bong Sang ;
Choi, Hong Seok .
ANTICANCER RESEARCH, 2020, 40 (09) :5081-5090
[6]   In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates [J].
Chandramohan, Yuvaraj ;
Padmanaban, Venkatesan ;
Bethunaickan, Ramalingam ;
Tripathy, Srikanth ;
Swaminathan, Soumya ;
Ranganathan, Uma Devi .
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2019, 19 :348-353
[7]   Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong [J].
Chang, Kwok-Chiu ;
Leung, Eric Chung-Ching ;
Law, Wing-Sze ;
Leung, Wai-Man ;
Tai, Lai-Bun ;
Lee, Shuk-Nor ;
Lam, Fai-Man ;
Chau, Chi-Hung ;
Mok, Thomas Yun-Wing ;
Yew, Wing-Wai ;
Leung, Chi-Chiu .
EUROPEAN RESPIRATORY JOURNAL, 2018, 51 (06)
[8]   Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection, and Management [J].
Curigliano, Giuseppe ;
Cardinale, Daniela ;
Dent, Susan ;
Criscitiello, Carmen ;
Aseyev, Olexiy ;
Lenihan, Daniel ;
Cipolla, Carlo Maria .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (04) :310-325
[9]   From Oxiranes to Oligomers: Architectures of US FDA Approved Pharmaceuticals Containing Oxygen Heterocycles [J].
Delost, Michael D. ;
Smith, David T. ;
Anderson, Benton J. ;
Njardarson, Jon T. .
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (24) :10996-11020
[10]   Patient-reported outcomes in the evaluation of toxicity of anticancer treatments [J].
Di Maio, Massimo ;
Basch, Ethan ;
Bryce, Jane ;
Perrone, Francesco .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (05) :319-325